3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
9
Neoplasm Metastasis
7
Brain Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Glioblastoma
3
Carcinoma, Non-Small-Cell Lung
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Prostatic Neoplasms
2
Hereditary Sensory and Autonomic Neuropathies
2
Tongue Neoplasms
1
Thymoma
1
Skin Neoplasms
1
Salivary Gland Neoplasms
1
Neoplasms
1
Nasopharyngeal Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Laryngeal Neoplasms
1
Hypoxia
1
Hypopharyngeal Neoplasms
1
Hematologic Neoplasms
1
Gliosarcoma
1
Interventions
Alpelisib
4
berzosertib
3
Fulvestrant
3
Everolimus
3
parsaclisib
2
Topotecan
2
NVP-BKM120
2
Cetuximab
2
talazoparib
1
sotorasib
1
serabelisib
1
ruxolitinib
1
duvelisib
1
dapagliflozin
1
cobimetinib
1
ceralasertib
1
binimetinib
1
avelumab
1
Vemurafenib
1
SF 1126
1
Rituximab
1
Paclitaxel
1
Oxaliplatin
1
Leuprolide
1
Leucovorin
1
Letrozole
1
Irinotecan
1
Goserelin
1
Fluorouracil
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Hereditary Sensory and Autonomic Neuropathies
×
NVP-BKM120
×
Clear all
NCT01633060
2019-01-30
BELLE-3
Novartis
Phase 3
Terminated
432 enrolled
20 charts
NCT01572727
2017-03-09
BELLE-4
Novartis
Phase 2/3
Completed
416 enrolled
11 charts